Results 201 to 210 of about 2,234,624 (258)

Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic response to the cytotoxic threat. [PDF]

Oncol Rep
Röttgen H, Theurer L, Peccerella T, Sandu K, Weiss J, Burhenne J, Neoptolemos JP, Köberle B, Theile D.   +8 more
europepmc   +1 more source

KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine

MedComm, Volume 7, Issue 10, October 2026.
KRAS‐mutant cancers are therapeutically shaped by both allele identity and tumor context. Direct KRAS inhibition has achieved the greatest clinical success in KRAS G12C‐mutant NSCLC, whereas colorectal cancer often requires EGFR cotargeting and pancreatic cancer remains constrained by stromal and metabolic barriers. Shared resistance mechanisms include
Jiaying Cai, Yimin Wu, Xing Jia, Li Yang, Wenjun Yang, Weishan Lu, Zhiye Huang, Yang Pan, Zixuan Fei, Junnan Ru, Jiazheng Zhao, Jue Shen, Taobo Luo, Da Chen, Haihong Yu, Haihan Deng, Jian Zeng, Wenmei Jiang, Leilei Wu   +18 more
wiley   +1 more source

Correction: An integrative analysis of transcriptome, methylome and single-cell RNA sequencing data identifies UBE2H as a marker of oxaliplatin resistance in colorectal cancer. [PDF]

Cancer Cell Int
Fang J, Zhu Q, Hong B, Li X, Wang H.
europepmc   +1 more source

Intratumoral Microbiota in Fueling Cancer and Steering Treatment Response

MedComm, Volume 7, Issue 10, October 2026.
Emerging research underscores the tumor‐specific colonization of microbiota and the role of intratumoral microbiota in cancer development and treatment resistance across multiple malignancies. Here, we provide a systematic review exploring the latest biotechnological advancements for studying low‐abundance intratumoral microbiota, their origins ...
Minhui Xu, Jie Yu, Ying Chen, Shengfang Ge, Lin Ye, Yefei Wang, Yixiong Zhou, Renbing Jia   +7 more
wiley   +1 more source

Multi-omics analysis of patient-derived organoids reveals that E3 ligase COP1 promotes liver metastasis and oxaliplatin resistance in colorectal cancer through LUZP1 degradation and MYL9 phosphorylation. [PDF]

Exp Hematol Oncol
Zhang R, Luo W, Zhou Q, Liang D, Hao Y, Chen F, Qiu Y, Cao Y, Shan Z, Zhang Y, Li Q, Cai S, Luo D, Mo S, Ma B, Li X.   +15 more
europepmc   +1 more source

Efficacy and Safety of Fruquintinib Plus TAS‐102 in Patients With Previously Treated Metastatic Colorectal Cancer: Results From a Single‐Arm, Multi‐Center, Phase II Study

MedComm, Volume 7, Issue 10, October 2026.
This study is the first prospective clinical trial that evaluated the efficacy and safety of fruquintinib combined with TAS‐102 in the later‐line treatment of patients with mCRC. Fruquintinib plus TAS‐102 demonstrated promising efficacy and manageable safety profile in patients with mCRC who had failed at least two standard therapies, supporting its ...
Jianjun Peng, Yong Li, Ling Huang, Jianhua Liu, Jianjun Xiao, Derong Xie, Wei Wang, Zongcheng Zhang, Chengyin Weng, Xiaoshu Chai, Huifen Li, Xiaomei Jiang, Yan Qian, Risheng Zhao, Sile Chen, Zhimin Jiang, Lingdan Le, Xueqin Li, Jianting Long, Haibo Zhang, Chuangqi Chen, Shirong Cai   +21 more
wiley   +1 more source

Cigarette smoke extract promotes metastasis and oxaliplatin resistance in colon adenocarcinoma through GDF15/ERBB2/AKT pathway. [PDF]

Eur J Med Res
Jiang W, Wang Y, Wang WJ, Zhou BC, Hu XS, Xu AM.   +5 more
europepmc   +1 more source

Integrated Multi‐Time‐Point 18F‐FAPI PET/CT and Immune Histopathology for Predicting Pathological Complete Response in Microsatellite‐Stable Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy, Chemotherapy, and Immunotherapy

MedComm, Volume 7, Issue 10, October 2026.
Serial multi‐time‐point 18F‐FAPI PET/CT‐derived stromal kinetics and baseline immune‐histopathological features, including iTLS count and B‐cell density, jointly predicted pCR in MSS locally advanced rectal cancer. The resulting four‐variable model achieved a mean nested cross‐validated AUC of 0.874.
Minyi He, Huiting Yang, Yunxing Shi, Rongqin Zhang, Taixuan Wan, Xiaolin Pang, Zhanwen Zhang, Liang Huang   +7 more
wiley   +1 more source

Overexpression of Protein Kinase C iota as a prognostic marker and its role in oxaliplatin resistance in colorectal cancer. [PDF]

BMC Gastroenterol
Liao X, Liu M, Hong C, Liu Y, Li Q, Chen Y, Zhang T, Chen H, Fu S.   +8 more
europepmc   +1 more source

Fruquintinib: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Fruquintinib is a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3) that was approved, including in China, the United States, and the European Union, for the treatment of previously treated metastatic colorectal cancer (mCRC).
Xiaofei Zhou, Arvind Dasari, Jin Li, Caly Chien, Qi Dong, Lucy Chen, Lixian Dong, Neeraj Gupta   +7 more
wiley   +1 more source